Avacta shares drop 30% after lateral flow test blow
Shares in cancer therapies and diagnostics company Avacta (AVCT:AIM) sank 30% to 81.4p after it said laboratory analysis showed its proprietary lateral flow test was less effective at detecting lower viral loads of the Omicron variant.Today's announcement also knocked the shares of leading lateral flow test manufacturer and developer Abingdon Health (ABDX:AIM) which was scaling up the...